Marinaş M C, Mogoş G, Ciurea Raluca, Mogoş D G
Department of Obstetrics and Gynecology, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Rom J Morphol Embryol. 2012;53(3):563-7.
In this study, we analyzed EGFR, HER2/neu and Ki67 immunoexpression for 26 benign, borderline and malignant serous ovarian tumors. EGFR and HER2/neu immunoreactions were present in some benign/borderline tumors with high/low intensity of immunostain. In poorly differentiated adenocarcinomas, the EGFR/HER2/neu reaction was intense compared to well-differentiated ones. The Ki67 medium proliferation index was 2.1% for benign tumors, 6% in the borderline and 47.7% in malignant tumors. EGFR, HER2/neu and Ki67 can be used to identify benign/borderline tumors with progression potential and the malignant aggressive tumors.
在本研究中，我们分析了26例良性、交界性和恶性浆液性卵巢肿瘤的表皮生长因子受体（EGFR）、人表皮生长因子受体2/神经生长因子受体（HER2/neu）和Ki67免疫表达情况。在一些良性/交界性肿瘤中，EGFR和HER2/neu免疫反应呈高/低强度免疫染色。在低分化腺癌中，与高分化腺癌相比，EGFR/HER2/neu反应强烈。良性肿瘤的Ki67平均增殖指数为2.1%，交界性肿瘤为6%，恶性肿瘤为47.7%。EGFR、HER2/neu和Ki67可用于识别具有进展潜能的良性/交界性肿瘤以及恶性侵袭性肿瘤。
